Results 11 to 20 of about 14,385 (213)
Leukemia, 2022 Radioimmunotherapy (RIT) has long been pursued to improve outcomes in acute leukemia and higher-risk myelodysplastic syndrome (MDS). Of increasing interest are alpha-particle-emitting radionuclides such as astatine-211 (211At) as they deliver large amounts of radiation over just a few cell diameters, enabling efficient and selective target cell kill ...
George S. Laszlo +12 more
openaire +3 more sources
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells [PDF]
Nature Communications, 2022 AbstractBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially expressed on the surface of BPDCN cells, it has emerged as an attractive therapeutic target ...
Tianyu Cai +32 more
openaire +6 more sources
Drug Delivery, 2017 A novel niosomal delivery system was designed and investigated for the targeted delivery of daunorubicin (DNR) against acute myeloid leukemia (AML). Anti-CD123 antibodies conjugated to Mal-PEG2000-DSPE were incorporated into normal niosomes (NS) via a ...
Fu-rong Liu +7 more
doaj +2 more sources
Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia
Human Vaccines & Immunotherapeutics, 2020 The IL-3 alpha chain receptor (CD123) is a cell surface protein that is widely expressed by various subtypes of acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia and blastic plasmacytoid dendritic cell neoplasm. Notably,
Ibrahim Aldoss +3 more
doaj +2 more sources
Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones [PDF]
Journal of Hematology & Oncology, 2016 Background Acute myeloid leukemia (AML) is a heterogeneous clonal disorder presenting with accumulation of proliferating undifferentiated blasts. Xenograft transplantation studies have demonstrated a rare population of leukemia-initiating cells called ...
Adhra Al-Mawali, David Gillis, Ian Lewis
doaj +2 more sources
Drug Delivery, 2017 Since conventional chemotherapy for acute myeloid leukemia (AML) has its limitations, a theranostic platform with targeted and efficient drug transport is in demand.
Haibin Wu +10 more
doaj +2 more sources
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo [PDF]
Journal for ImmunoTherapy of Cancer, 2020 Background Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies ...
Pablo Menendez +23 more
doaj +3 more sources
Haematologica, 2019 The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large cohort of patients with acute lymphoblastic leukemia/lymphoma and assessed the in vitro impact ...
Evgeniya Angelova +14 more
doaj +4 more sources
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies [PDF]
Cancers, 2019 The interleukin-3 receptor alpha chain (IL-3R), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin lymphoma and particularly, blastic plasmacytoid dendritic neoplasm (BPDCN).
Ugo Testa +2 more
openaire +3 more sources
Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients
Advances in Hematology, 2020 This study aimed to determine the clinical impact of CD25+/CD123+ coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study.
Salah Aref +4 more
doaj +2 more sources